急性冠脉综合征患者的抗血小板治疗:最新进展

Adnan Bashar, Md. Harisul Hoque, M. Chowdhury, A. Hasan, Khurshed Ahmed
{"title":"急性冠脉综合征患者的抗血小板治疗:最新进展","authors":"Adnan Bashar, Md. Harisul Hoque, M. Chowdhury, A. Hasan, Khurshed Ahmed","doi":"10.3329/uhj.v17i1.50884","DOIUrl":null,"url":null,"abstract":"Antiplatelet therapy is the cornerstone in the treatment of acute coronary syndrome. Aspirin is the most widely used antiplatelet agent followed by P2Y12 inhibitors. Glycoprotein (GP) IIb-IIIa antagonists are also gaining popularity as an antiplatelet agents during peri-PCI period. This review article summarizes the indications, duration of dual antiplatelet therapy (DAPT) in ACS setting. Antiplatelet therapy in special situations like atrial fibrillation and thrombocytopenia are discussed here. Issues like switching between P2Y12 inhibitors and genetic testing of antiplatelet agents are also mentioned in this article \nUniversity Heart Journal Vol. 17, No. 1, Jan 2021; 66-70","PeriodicalId":23424,"journal":{"name":"University Heart Journal","volume":"36 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antiplatelet Therapy in Patients with Acute Coronary Syndrome: An Update\",\"authors\":\"Adnan Bashar, Md. Harisul Hoque, M. Chowdhury, A. Hasan, Khurshed Ahmed\",\"doi\":\"10.3329/uhj.v17i1.50884\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Antiplatelet therapy is the cornerstone in the treatment of acute coronary syndrome. Aspirin is the most widely used antiplatelet agent followed by P2Y12 inhibitors. Glycoprotein (GP) IIb-IIIa antagonists are also gaining popularity as an antiplatelet agents during peri-PCI period. This review article summarizes the indications, duration of dual antiplatelet therapy (DAPT) in ACS setting. Antiplatelet therapy in special situations like atrial fibrillation and thrombocytopenia are discussed here. Issues like switching between P2Y12 inhibitors and genetic testing of antiplatelet agents are also mentioned in this article \\nUniversity Heart Journal Vol. 17, No. 1, Jan 2021; 66-70\",\"PeriodicalId\":23424,\"journal\":{\"name\":\"University Heart Journal\",\"volume\":\"36 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-12-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"University Heart Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3329/uhj.v17i1.50884\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"University Heart Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3329/uhj.v17i1.50884","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

抗血小板治疗是治疗急性冠脉综合征的基石。阿司匹林是应用最广泛的抗血小板药物,其次是P2Y12抑制剂。糖蛋白(GP) IIb-IIIa拮抗剂在pci围术期作为抗血小板药物也越来越受欢迎。本文就急性冠脉综合征(ACS)患者双重抗血小板治疗(DAPT)的适应症、疗程进行综述。在特殊情况下抗血小板治疗,如心房颤动和血小板减少在这里讨论。这篇文章也提到了P2Y12抑制剂和抗血小板药物基因检测之间的切换问题,《大学心脏杂志》第17卷,第1期,2021年1月;66 - 70
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Antiplatelet Therapy in Patients with Acute Coronary Syndrome: An Update
Antiplatelet therapy is the cornerstone in the treatment of acute coronary syndrome. Aspirin is the most widely used antiplatelet agent followed by P2Y12 inhibitors. Glycoprotein (GP) IIb-IIIa antagonists are also gaining popularity as an antiplatelet agents during peri-PCI period. This review article summarizes the indications, duration of dual antiplatelet therapy (DAPT) in ACS setting. Antiplatelet therapy in special situations like atrial fibrillation and thrombocytopenia are discussed here. Issues like switching between P2Y12 inhibitors and genetic testing of antiplatelet agents are also mentioned in this article University Heart Journal Vol. 17, No. 1, Jan 2021; 66-70
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信